- Home
- CTXR vs NCNA Comparison
CTXR vs NCNA Comparison
Compare CTXR & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTXR
- NCNA
- Stock Information
- Founded
- CTXR 2007
- NCNA 1997
- Country
- CTXR United States
- NCNA United Kingdom
- Employees
- CTXR N/A
- NCNA N/A
- Industry
- CTXR Biotechnology: Pharmaceutical Preparations
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- CTXR Health Care
- NCNA Health Care
- Exchange
- CTXR Nasdaq
- NCNA Nasdaq
- Market Cap
- CTXR 18.7M
- NCNA 15.4M
- IPO Year
- CTXR N/A
- NCNA 2017
- Fundamental
- Price
- CTXR $1.35
- NCNA $3.44
- Analyst Decision
- CTXR Strong Buy
- NCNA Buy
- Analyst Count
- CTXR 3
- NCNA 2
- Target Price
- CTXR $53.00
- NCNA $5,000.00
- AVG Volume (30 Days)
- CTXR 360.0K
- NCNA 738.4K
- Earning Date
- CTXR 08-12-2025
- NCNA 08-20-2025
- Dividend Yield
- CTXR N/A
- NCNA N/A
- EPS Growth
- CTXR N/A
- NCNA N/A
- EPS
- CTXR N/A
- NCNA N/A
- Revenue
- CTXR N/A
- NCNA N/A
- Revenue This Year
- CTXR N/A
- NCNA N/A
- Revenue Next Year
- CTXR $851.67
- NCNA N/A
- P/E Ratio
- CTXR N/A
- NCNA N/A
- Revenue Growth
- CTXR N/A
- NCNA N/A
- 52 Week Low
- CTXR $0.65
- NCNA $3.05
- 52 Week High
- CTXR $17.00
- NCNA $1,856.00
- Technical
- Relative Strength Index (RSI)
- CTXR 49.89
- NCNA 30.79
- Support Level
- CTXR $1.18
- NCNA $3.05
- Resistance Level
- CTXR $1.45
- NCNA $3.78
- Average True Range (ATR)
- CTXR 0.10
- NCNA 0.82
- MACD
- CTXR -0.00
- NCNA 0.11
- Stochastic Oscillator
- CTXR 62.96
- NCNA 5.61
About CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.